| Summary: | Because of drug resistance, currently available anticancer therapies-drugs, radiotherapy, and other biological agents-have limited efficacy in treating cancer. In DNA Repair in Cancer Therapy, leading cancer researchers and oncologists comprehensively review the many recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limit its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Inhibitors of such other DNA repair enzymes as PARP and DNA-PK, now under development and close to clinical trials, are also examined. Comprehensive and cutting-edge, DNA Repair in Cancer Therapy surveys-for both cancer researchers and practicing oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies
|
|---|